The Beachbody Company (BODI) – Finding Its Footing in Retail


Tuesday, August 11, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another profitable quarter. Q2 revenue of $49.6 million exceeded the midpoint of guidance, while adjusted EBITDA of $6.7 million exceeded the high end and marked the company’s 11th consecutive quarter of positive adjusted EBITDA. While revenues were in line, the company exceeded our $4.5 million adj. EBITDA estimate. 

Retail traction encouraging. Shakeology distribution expanded to 131 Sprouts stores, with early reorders supporting favorable sell-through, while the company recently launched in 481 Vitamin Shoppe locations. Approximately 12 additional retail decisions are expected between mid-September and late November.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Summit Midstream Corp (SMC) – Improving Growth Outlook and Operational Momentum


Tuesday, August 11, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second Quarter FY 2026 Financial Results. Summit Midstream generated $155.0 million of revenue, up 10.6% from the prior-year quarter, and reported net income attributable to Summit Midstream Corp. of $1.6 million, or $0.11 per share, compared with a net loss of $8.0 million, or $(0.66) per share, during the prior year period. Adj. EBITDA amounted to $60.7 million compared to $61.1 million during the prior year period, as stronger Rockies and Permian performance was offset by weaker Mid-Con and Piceance segment results. We had forecast revenue of $144.4 million and adj. EBITDA of $59.7 million. Distributable cash flow increased to $36.8 million from $32.4 million, and free cash flow increased modestly to $9.4 million compared to $9.2 million during the second quarter of 2025. Sequentially, SMC’s second quarter results demonstrated meaningful improvement, supported by stronger producer activity and higher throughput volume across much of the portfolio.  

Guidance Narrowed. Management narrowed its FY 2026 guidance range for adj. EBITDA to $235 million to $255 million from $225 million to $265 million, and increased capital expenditure guidance to $100 million to $120 million from $85 million to $105 million. The increased capital budget is primarily tied to approximately 30 additional Williston Basin well connections and incremental investment in the Double E pipeline, while accelerating producer activity, additional firm transportation agreements, and a potential Double E compression expansion support the longer-term growth outlook.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NeuroSense Therapeutics Ltd. (NRSN) – NeuroSense Announces Target Date For Canadian PrimeC Approval Application


Tuesday, August 11, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Pre-Application Process Has Been Completed. NeuroSense announced that it has completed Pre-NDS meetings with Health Canada and plans to submit a New Drug Submission (NDS) for PrimeC in its ALS indication. These meetings focused on whether the data could support approval and the submission requirements. The target date is December 2026. We see this as good news that is consistent with our expectations.

We View The Canadian NDS Process As An Important Milestone For PrimeC. The NDS application will include the Phase 2b PARADIGM trial data, with additional preclinical and supporting data. The primary endpoint in the trial showed a reduction in TDP-43 (TAR DNA-binding Protein 43, a protein that drives ALS progression and deterioration). The data also showed increased median survival, improved functional assessments, biomarkers showing slower disease progression, as well as safety and tolerability. Approval would be based on Health Canada’s analysis of these data.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NanoViricides (NNVC) – NanoViricides Receives Regulatory Approval To Begin Phase 2 For Ebola In Africa


Tuesday, August 11, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Regulatory Approval Allows the Phase 2 Trial for NV-387 To Begin. NanoViricides has received approval to proceed with its Phase 2 trial of NV-387 for the treatment of Ebola in the Democratic Republic of Congo (DRC). We expect the Ebola trial to be followed by a separate Phase 2 trial in Mpox, also to be conducted in the DRC. This is consistent with our expected time frame for the trials.

Previous Preparations Should Allow Treatment To Start Soon. NanoViricides has completed delivery of clinical supplies of NV-387 oral solid formulation (gummies) for treatment of the trial. The trial will be conducted by OM Sai Clinical Research, a contract research organization (CRO) based in India. The CRO has assembled a clinical team with a Principal Investigator, local clinicians, and a university in the region to support the trial. The approval by ACOREP (Autorité Congolaise de Réglementation Pharmaceutique, the Congolese Pharmaceutical Regulatory Authority) should allow the trial to start patient treatment shortly.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – $500 Million Accelerated Share Repurchase


Tuesday, August 11, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

ASR. CoreCivic has decided how to use a portion of the proceeds from the facilities sale, and it’s a $500 million Accelerated Share Repurchase program. The Company already used over $600 million of net proceeds to reduce debt, and increased share repurchases were a logical use of additional funds, in our opinion. Upon completion of the ASR Agreement, the Company anticipates that approximately $255.8 million of share repurchase authorization will remain available.

Details. The Company made a payment of $500 million to a financial institution on August 10, 2026, and expects to receive an initial delivery of approximately 12.4 million shares of CXW common stock (about 12.5% of the outstanding) from the financial institution, pursuant to the ASR Agreement. Based on Friday’s closing price, the initial 12.4 million shares would have used approximately $400 million of the $500 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Conduent (CNDT) – Execution Takes Center Stage


Tuesday, August 11, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Execution continues to improve. Management reiterated that second quarter results were in line with expectations while highlighting meaningful progress across its five strategic priorities, including cost reduction, financial discipline, portfolio optimization, and pipeline conversion. Six months into the transformation, management believes the company is beginning to see tangible operational improvements.

Transportation exit strengthens the financial profile. The announced sales of the Transit and Tolling businesses are expected to generate approximately $234 million of gross proceeds, reduce off-balance-sheet obligations by roughly 80%, lower capital requirements, and provide significant flexibility to reduce debt while sharpening management’s focus on its core businesses.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Back-to-School and the Stock Market: Is There Really a September Effect?

Every August, the same scene plays out: parents load up shopping carts with notebooks and sneakers, and almost like clockwork the stock market starts to wobble. Investors call this the “September Effect,” and it’s one of the most searched market patterns every fall. So is there really a connection between back-to-school season and the stock market? Here’s what the data says.

Is September Really the Worst Month for the Stock Market?

Since 1928, the S&P 500 has averaged a return of roughly -1.1% in September, by far the worst of any month on the calendar, and the only month with a meaningfully negative long-run average. August and September together have been the weakest back-to-back stretch since 1945. The index has closed lower in September more than half the time since 1928, no other month drops that often.

This year, back-to-school spending is bigger than ever. The National Retail Federation projects total 2026 back-to-school spending, kindergarten through college, will hit $146.8 billion, up from $128.2 billion in 2025, with college spending crossing $100 billion for the first time. So does all that retail activity actually move the market? Not directly, but the timing overlap is too consistent to ignore.

Why Does the Stock Market Drop in September? 3 Theories

1. Traders come back from summer vacation. The most credible explanation has nothing to do with school supplies and everything to do with vacation schedules. Trading volume and volatility run low through the summer as fund managers and everyday investors take time off. When everyone returns after Labor Day, that quiet gives way to a concentrated wave of rebalancing, all landing in the same few weeks.

2. Household spending shifts to essentials. As families shift spending toward school supplies and tuition, discretionary spending elsewhere slows, and consumer routines reset to budget-conscious mode. Some analysts argue that shift filters into earnings expectations right as September begins. It’s a compelling theory, but worth being honest about, it’s a theory, not a proven cause.

3. Mutual funds “window dress” before fiscal year-end. Many mutual funds close their fiscal year on September 30th, and beforehand, managers often trim losers and buy winners to make year-end portfolios look better, a practice known as “window dressing.” That selling pressure adds to September weakness for reasons that have nothing to do with backpacks or lunchboxes.

Does the September Effect Actually Predict Market Crashes?

Not on its own. Some of September’s worst historical drops happened during bear markets already underway for entirely unrelated reasons, the Great Depression, the dot-com crash, the 2008 financial crisis. The calendar didn’t cause those crashes; it just happened to be the backdrop. When the broader market has strong momentum heading into September, the seasonal weakness has historically shown up far less, if at all.

Should You Change Your Investing Strategy for September?

The back-to-school season and stock market weakness share a calendar and a shift in investor psychology, but the relationship is a tendency, not a rule. The smarter takeaway isn’t to sell in August and buy back in October. It’s to recognize seasonal patterns are noise layered on top of the real drivers: economic data, interest rates, and corporate earnings, and to stay invested through the noise rather than trying to trade around it.

This September, as retailers report record back-to-school numbers, the real story to watch isn’t the calendar. It’s what that spending says about the health of the consumer, because that, unlike seasonality, actually moves markets.

First Phosphate Corp. (FRSPF) – Nasdaq Uplisting Enhances and Expands Investor Access


Monday, August 10, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Nasdaq Listing. First Phosphate’s American Depositary Receipts (ADRs) will uplist to the Nasdaq Global Market under the ticker PHOS, effective August 10, 2026. The ADR ratio remains 10 common shares per ADR, and existing Level 1 ADRs will be delisted from the OTCQX and automatically converted to Level 2 ADRs for Nasdaq trading. First Phosphate’s currently listed common shares on the OTCQX, CSE, and Frankfurt Stock Exchange are unaffected. Uplisting to Nasdaq is expected to enhance U.S. market access for First Phosphate, which is developing a vertically integrated North American supply chain for LFP battery materials used for energy storage, data centers, robotics, mobility, and national security applications.

No New Capital. First Phosphate is the second self-sponsored ADR to uplist to Nasdaq and the first to do so without a concurrent capital raise. The Nasdaq uplisting does not involve issuing additional shares or raising new capital. Investors may continue converting First Phosphate common shares into ADRs at no cost through The Bank of New York Mellon, the depositary bank for the First Phosphate ADR program, until December 31, 2026. First Phosphate is well funded with more than C$30 million in treasury and access to C$21.5 million in Canadian government contributions, providing funding through a final investment decision (FID).


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – A New Era


Monday, August 10, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A New Era. NN delivered strong financial performance in the second quarter with record results in many areas. These new sales are higher margin, attached to higher growth rate end markets, and mostly immediate 2026 startup. The Company is achieving many multi-year goals and revising outlooks-including raising full-year guidance- based upon actual results. And, significantly, post-quarter-end management implemented what can only be described as a game-changing restructuring of the capital structure.

Growth. During the quarter, NN secured significant 2026 immediate-supply awards for Data Center liquid cooling products, robotic surgery medical products, and defense products. New business wins through July totaled $80 million. Management increased the full-year new business win goal from $80 million to the $100 million range.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kelly Services (KELYA) – Improving Momentum


Monday, August 10, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. In the second quarter of 2026, Kelly exceeded guidance for both revenue and adjusted EBITDA margin, driven by growing momentum from the Company’s growth and efficiency initiatives as well as constructive demand trends in parts of the portfolio. Notably, Kelly delivered sequential improvements in each of the business segments.

2Q26 Results. Revenue was $1.04 billion, down approximately 5.8% y-o-y, but significantly better than the expected 7-9% revenue decline.  We were at $1.01 billion. Adjusted EBITDA for 2Q26 was $16.1 million, a 3.0% margin, above management’s 2.5% projection. We were at $25 million and 2.5%. Adjusted EPS was $0.37 versus $0.54 in 2Q25. We had estimated $0.30.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – 2Q26 Results Exceed Expectations; Raising Price Target


Monday, August 10, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. As we highlighted in our First Look at CoreCivic’s operating results, the Company’s second quarter 2026 financial results exceeded management expectations, driven by lower operating costs and slightly higher populations from ICE. While the quarterly operating results were a positive in and of themselves, the major news came post-quarter’s end with the announcements of sales of four detention facilities to the Federal government for total gross proceeds of $2.2 billion and a net of approximately $1.6 billion. The Company remains in discussions with ICE for the potential sale of additional facilities, as well as for new contracts at existing and/or idle facilities.

Capital. With the facilities sold, the current capital structure has significantly changed. Net proceeds, after taxes and sale costs, were approximately $1.6 billion. The Company used $608.5 million to pay down debt, including $238.5 million of the 4.75% unsecured notes that will be repaid on August 12th. After income taxes and debt repayments, the Company will have approximately $1 billion of cash on hand, total debt outstanding of $739.1 million, and $553.3 million of borrowing capacity under the revolving credit facility.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

E.W. Scripps (SSP) – Transformation and Regulatory Change Create Long-Term Upside


Monday, August 10, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Mixed Q2 results, but EBITDA outlook remains intact. Second-quarter results reflected continued pressure in the Scripps Networks business from weak national advertising, retransmission disruptions, and Nielsen measurement changes. However, stronger political advertising guidance and accelerated transformation savings largely offset these headwinds, leading us to maintain our 2026 adjusted EBITDA estimate despite modest revenue revisions. 

Transformation plan gains momentum. Management increased its expected year-end transformation run-rate savings to $100 million, up from $75 million previously, reinforcing confidence in its target of delivering $125–150 million of incremental annualized EBITDA by 2028 through AI, automation, and operational modernization. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Graham (GHM) – Strong Start to Fiscal 2027


Monday, August 10, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Graham’s first quarter results reflect continued disciplined execution. The Company experienced revenue growth across all business units, reflecting the strength of Graham’s diversified business model and strong demand for the Company’s mission-critical technologies. Bookings remained strong, and backlog was at a record level.

1Q27 Results. First quarter fiscal 2027 net sales were $71.3 million, up $15.9 million, or 29%. We had projected $66 million. 1Q27 adjusted EBITDA increased 28% to $8.8 million, representing an adjusted EBITDA margin of 12.3%, which was consistent with the prior year period. We were at $8.3 million and 12.7%. Graham reported 1Q27 adjusted net income of $5.7 million, or $0.49/sh, compared with $4.9 million and $0.45/sh last year. This exceeded our $5.1 million and $0.43/sh estimate.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.